You are here: Home » Blog

OracleBio presenting at the 4th Annual Definiens Symposium

Written by on · Leave a Comment

Definiens Symposium BannerWe are please to announce that OracleBio’s Chief Scientific Officer, Dr. Lorcan Sherry, will be presenting at the 4th International Definiens Symposium to be held in Boston, 13th – 15th May. 

Definiens will host more than 20 distinguished speakers at the  Symposium, to be held at Joseph B. Martin Conference center on the Harvard Medical School campus. Presenters will highlight how Definiens technology is used in practice to accelerate R&D and discovery of new drugs and biomarkers in automated workflows and how it can be used to innovate new diagnostic tests, increase the success rate of development, reduce time to market and manage the diversity of a broad range of image analysis tasks.

Lorcan’s presentation is entitled ‘Analysis of Drug Response Read-Outs in Xenograft Tissue using Definiens Tissue Studio‘ and will highlight some of OracleBio’s experiences in using Tissue Studio for evaluation of common Xenograft drug response read-outs including evaluation of necrotic and viable tumour regions, proliferation, angiogenesis and biomarker expression. Furthermore, how Tissue Studio can be used to help address specific issues across large batch analysis.

Image Analysis Insights – OracleBio’s Newsletter

Written by on · Leave a Comment

Welcome to the first edition of  Image Analysis Insights, OracleBio’s new quarterly newsletter providing informative insights into the application of image analysis in R&D and biomarker research. In this edition, we highlight how image analysis plays a key part in R&D studies and in particular, the increasing application of image analysis in Oncology. You’ll also [...] Read more »

Image Analysis Applications in Drug Discovery

Written by on · Leave a Comment

Quantification of histomorphometry and IHC marker staining read outs within cells and tissues is an essential read out across many Pharmaceutical R&D studies. Continued advances in digital image analysis software, in combination with whole slide imaging, now allows for highly accurate, objective and rapid assessment of marker staining across whole tissue sections on a cell [...] Read more »

FDA issues draft guidance on the use of histology in biomarker qualification studies

Written by on · Leave a Comment

In recent years there has been a significant increase in the use of histological approaches in the generation of data to support the characterisation, validation and qualification of diagnostic, prognostic and predictive biomarkers, to be used as in both the clinical and pre-clinical setting. In response to this increase, in December 2011 the Food and [...] Read more »

Microscope Slide Scanning – Will Microscope Slide Storage Become a Thing of The Past?

Written by on · Leave a Comment

Digitally scanning microscope slides to produce digital histology images is a recent technology which is of interest to both histologists and pathologists. Virtual microscopy is routinely used in various teaching organisations, however its implementation and utilization in everyday histology/pathology laboratories is still in its infancy. There are numerous opinions and preconceptions on the matter and [...] Read more »

Quantification of Beta Amyloid Plaques in Alzheimer’s disease by Definiens image analysis

Written by on · Leave a Comment

Detection of Beta-Amyloid (Aβ) plaques in Alzheimer’s Disease (AD) using Immunohistochemistry (IHC) and image analysis was the subject of a recent publication in the Journal of Neuroscience Methods, 2011 (http://www.ncbi.nlm.nih.gov/pubmed/22019329) by Samaroo et al. at Pfizer. They applied a high throughput object-based image analysis methodology using Definiens software and validated it to quantify immunohistochemically stained β-Amyloid [...] Read more »

Xenograft IHC image analysis and getting the most out of R&D studies

Written by on · Leave a Comment

Pre-clinical Xenograft Tumor models coupled with immunohistochemistry (IHC) and quantitative image analysis is an established approach within many Oncology focused Pharmaceutical R&D programs to investigate factors involved in malignant transformation, invasion and metastasis, as well as to examine response to therapy. However, achieving robust, detailed and consistent results from study to study depends on a [...] Read more »